Phaseline

Companies › Seqker Biosciences

Seqker Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Personalized Neoantigen Peptide Vaccine
Personalized synthetic long peptides derived from patient-specific tumor neoantigens to st
–Phase 1Solid TumorsAug 2027
Poly-ICLC (Hiltonol)
TLR3 and RIG-I-like receptor agonist; immune adjuvant
IFIH1, DDX58Phase 1Solid Tumors; Follicular Lymphoma; Lymphocytic LeukemiaAug 2027
anti-PD-1 immune checkpoint inhibitor
PD-1 checkpoint inhibitor
PDCD1Phase 1Solid TumorsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03361852Poly-ICLC (Hiltonol)Phase 1Follicular LymphomaOncologyDec 2026
NCT03219450Poly-ICLC (Hiltonol)Phase 1Lymphocytic LeukemiaOncologyJul 2027
NCT07002203Personalized Neoantigen Peptide VaccinePhase 1Solid TumorsOncologyAug 2027
NCT07002203Poly-ICLC (Hiltonol)Phase 1Solid TumorsOncologyAug 2027
NCT07002203anti-PD-1 immune checkpoint inhibitorPhase 1Solid TumorsOncologyAug 2027

Targets

IFIH1 (1) DDX58 (1) PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.